These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21041084)

  • 1. Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease.
    Beaulieu C; Isabel E; Fortier A; Massé F; Mellon C; Méthot N; Ndao M; Nicoll-Griffith D; Lee D; Park H; Black WC
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7444-9. PubMed ID: 21041084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of reversible inhibitors of IdeS, a bacterial cysteine protease and virulence determinant.
    Berggren K; Johansson B; Fex T; Kihlberg J; Björck L; Luthman K
    Bioorg Med Chem; 2009 May; 17(9):3463-70. PubMed ID: 19362485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
    Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
    Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptidomimetic nitrile inhibitors of malarial protease falcipain-2 with high selectivity against human cathepsins.
    Nizi E; Sferrazza A; Fabbrini D; Nardi V; Andreini M; Graziani R; Gennari N; Bresciani A; Paonessa G; Harper S
    Bioorg Med Chem Lett; 2018 May; 28(9):1540-1544. PubMed ID: 29615344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ligand-induced conformational selection predicts the selectivity of cysteine protease inhibitors.
    Sartori GR; Leitão A; Montanari CA; Laughton CA
    PLoS One; 2019; 14(12):e0222055. PubMed ID: 31856175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-Masked Aldehyde Inhibitors: A Novel Strategy for Inhibiting Cysteine Proteases.
    Li L; Chenna BC; Yang KS; Cole TR; Goodall ZT; Giardini M; Moghadamchargari Z; Hernandez EA; Gomez J; Calvet CM; Bernatchez JA; Mellott DM; Zhu J; Rademacher A; Thomas D; Blankenship LR; Drelich A; Laganowsky A; Tseng CK; Liu WR; Wand AJ; Cruz-Reyes J; Siqueira-Neto JL; Meek TD
    J Med Chem; 2021 Aug; 64(15):11267-11287. PubMed ID: 34288674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease.
    Nicoll-Griffith DA
    Expert Opin Drug Discov; 2012 Apr; 7(4):353-66. PubMed ID: 22458506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylaminoethyl amides as noncovalent inhibitors of cathepsin S. Part 2: Optimization of P1 and N-aryl.
    Alper PB; Liu H; Chatterjee AK; Nguyen KT; Tully DC; Tumanut C; Li J; Harris JL; Tuntland T; Chang J; Gordon P; Hollenbeck T; Karanewsky DS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1486-90. PubMed ID: 16412634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and SAR exploration of a novel series of Legumain inhibitors.
    Eddie SL; Gregson A; Graham E; Burton S; Harrison T; Burden R; Scott CJ; Mullan PB; Williams R
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1546-1548. PubMed ID: 31005445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptidomimetic 2-cyanopyrrolidines as potent selective cathepsin L inhibitors.
    Yadav MR; Shinde AK; Chouhan BS; Giridhar R; Menard R
    J Enzyme Inhib Med Chem; 2008 Apr; 23(2):190-7. PubMed ID: 18343903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative study of warheads for design of cysteine protease inhibitors.
    Silva DG; Ribeiro JFR; De Vita D; Cianni L; Franco CH; Freitas-Junior LH; Moraes CB; Rocha JR; Burtoloso ACB; Kenny PW; Leitão A; Montanari CA
    Bioorg Med Chem Lett; 2017 Nov; 27(22):5031-5035. PubMed ID: 29054358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.
    Löser R; Schilling K; Dimmig E; Gütschow M
    J Med Chem; 2005 Dec; 48(24):7688-707. PubMed ID: 16302809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation.
    Ettari R; Pinto A; Previti S; Tamborini L; Angelo IC; La Pietra V; Marinelli L; Novellino E; Schirmeister T; Zappalà M; Grasso S; De Micheli C; Conti P
    Bioorg Med Chem; 2015 Nov; 23(21):7053-60. PubMed ID: 26432608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors.
    Rocha DA; Silva EB; Fortes IS; Lopes MS; Ferreira RS; Andrade SF
    Eur J Med Chem; 2018 Sep; 157():1426-1459. PubMed ID: 30282318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thiosemicarbazone derivatives: Evaluation as cruzipain inhibitors and molecular modeling study of complexes with cruzain.
    Jasinski G; Salas-Sarduy E; Vega D; Fabian L; Martini MF; Moglioni AG
    Bioorg Med Chem; 2022 May; 61():116708. PubMed ID: 35334448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of rhodesain inhibitors with a 3-bromoisoxazoline warhead.
    Ettari R; Tamborini L; Angelo IC; Grasso S; Schirmeister T; Lo Presti L; De Micheli C; Pinto A; Conti P
    ChemMedChem; 2013 Dec; 8(12):2070-6. PubMed ID: 24243827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series.
    Coterón JM; Catterick D; Castro J; Chaparro MJ; Díaz B; Fernández E; Ferrer S; Gamo FJ; Gordo M; Gut J; de las Heras L; Legac J; Marco M; Miguel J; Muñoz V; Porras E; de la Rosa JC; Ruiz JR; Sandoval E; Ventosa P; Rosenthal PJ; Fiandor JM
    J Med Chem; 2010 Aug; 53(16):6129-52. PubMed ID: 20672841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The medicinal chemistry of the cathepsin cysteine proteases.
    Masuya K; Teno N
    Curr Top Med Chem; 2010; 10(7):695. PubMed ID: 20392199
    [No Abstract]   [Full Text] [Related]  

  • 19. Exploring inhibitor binding at the S' subsites of cathepsin L.
    Chowdhury SF; Joseph L; Kumar S; Tulsidas SR; Bhat S; Ziomek E; Ménard R; Sivaraman J; Purisima EO
    J Med Chem; 2008 Mar; 51(5):1361-8. PubMed ID: 18278855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease.
    Sbaraglini ML; Bellera CL; Fraccaroli L; Larocca L; Carrillo C; Talevi A; Alba Soto CD
    Int J Antimicrob Agents; 2016 Jul; 48(1):91-95. PubMed ID: 27216381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.